Featured Content

Winston Wong, PharmD
President, W-Squared Group

European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer

(Johnson & Johnson) Oct 17, 2014 - Janssen-Cilag International NV announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase (BTK) inhibitor.

Commentary: The clinicals for Imbruvica are strong. The safety profile is clean. We actually have an a therapeutic advancement...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

DNA Said to Protect Hispanic Women From Breast Cancer

(Wall Street Journal) Oct 20, 2014 - A genetic trait protects many women of Latin American descent from breast cancer, researchers probing the ethnic biology of cancer said Monday.
read article (paid subscription required) »

NewLink in $1 Billion Deal with Roche to Develop Cancer Drug

(Reuters) Oct 20, 2014 - NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer (Johnson & Johnson)

The clinicals for Imbruvica are strong. The safety profile is clean. We actually have an a therapeutic advancement...posted by: Winston Wong, PharmD

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma (Yahoo! Finance)

Two drugs which are very effective in their own right. Combined, project the results, and then the demand, and...posted by: Winston Wong, PharmD

ASCO Endorses CAP/IASLC/AMP Guideline on EGFR and ALK Molecular Testing for Patients with Lung Cancer (ASCO)

While I am glad to see ASCO endorsing such testing, such testing, from the eyes of the payer, is accepted as standard...posted by: Winston Wong, PharmD

'Parity' Laws for Costly Oral Cancer Drugs Not a Solution (Medscape Medical News)

Call it a shell game where the added cost liability of the payer is passed onto the general membership through...posted by: Winston, Wong, PharmD

Cancer Care Is Advancing, But Costs Cannot Be Ignored (Yahoo! Finance)

Dr Newcomer provides a powerful arguments addressing the advancement of oncology care, associated with increasing...posted by: Winston, Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Bayer Biopharmaceuticals, Inc. has posted 20 new jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 new jobs.


Novocure has posted 4 jobs.


View OBR Job Board>>


GH_edutorial_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
GTXI +19.21%
IMGN +13.98%
ARGS +10.43%
PARD -20.00%
CPXX -16.69%
MNKD -5.80%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: H2 2014
Company: Amgen
Product: Trebananib

Date: September / October 2014
Company: Seattle Genetics / Takeda
Product: Adcetris® (brentuximab vedotin)

Date: Q4 2014
Company: Bristol-Myers Squibb / Ono Pharmaceutical Co.
Product: Opdivo® (nivolumab)

See All OBR Radar items»